Marc Nash Sells 5,375 Shares of Outset Medical (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) EVP Marc Nash sold 5,375 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total transaction of $27,520.00. Following the completion of the transaction, the executive vice president owned 42,785 shares of the company’s stock, valued at $219,059.20. This trade represents a 11.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Marc Nash also recently made the following trade(s):

• On Wednesday, January 21st, Marc Nash sold 980 shares of Outset Medical stock. The stock was sold at an average price of $4.98, for a total transaction of $4,880.40.
• On Wednesday, January 7th, Marc Nash sold 108 shares of Outset Medical stock. The stock was sold at an average price of $4.27, for a total transaction of $461.16.
• On Monday, November 17th, Marc Nash sold 247 shares of Outset Medical stock. The shares were sold at an average price of $4.60, for a total transaction of $1,136.20.

Outset Medical Stock Up 3.8%

Shares of Outset Medical stock opened at $5.40 on Friday. Outset Medical, Inc. has a 1-year low of $3.10 and a 1-year high of $21.98. The company has a market capitalization of $98.01 million, a PE ratio of -0.41 and a beta of 2.07. The company has a debt-to-equity ratio of 0.69, a current ratio of 7.09 and a quick ratio of 5.77. The business has a 50-day moving average of $4.34 and a 200-day moving average of $10.99.

Institutional Investors Weigh In On Outset Medical

Several institutional investors and hedge funds have recently made changes to their positions in OM. Assenagon Asset Management S.A. lifted its stake in Outset Medical by 34.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company’s stock worth $1,886,000 after purchasing an additional 131,381 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Outset Medical by 1,276.1% during the third quarter. JPMorgan Chase & Co. now owns 116,306 shares of the company’s stock worth $1,642,000 after purchasing an additional 107,854 shares during the period. Alyeska Investment Group L.P. raised its holdings in shares of Outset Medical by 10.2% during the third quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock worth $22,798,000 after purchasing an additional 150,000 shares during the period. Millennium Management LLC lifted its position in shares of Outset Medical by 165.8% in the 3rd quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock worth $5,950,000 after buying an additional 262,874 shares during the last quarter. Finally, Citadel Advisors LLC boosted its holdings in shares of Outset Medical by 372.8% in the 3rd quarter. Citadel Advisors LLC now owns 96,084 shares of the company’s stock valued at $1,357,000 after buying an additional 75,762 shares during the period.

Key Headlines Impacting Outset Medical

Here are the key news stories impacting Outset Medical this week:

• Positive Sentiment: Intraday strength: OM is trading up today on relatively light volume, which may reflect a short-term technical bounce or buying into recent weakness. MarketBeat Trading Note
• Neutral Sentiment: Mixed analyst and technical backdrop — consensus ratings remain around “Moderate Buy” but recent downgrades and lower price targets have appeared; OM’s 50-day moving average (~$4.33) is well below its 200-day (~$11.03) and the stock sits nearer its 52‑week low than its high. These factors create mixed medium‑term pressure despite today’s move. MarketBeat Stock Page
• Negative Sentiment: CEO selling: CEO Leslie Trigg disclosed sales totaling 13,914 shares across Jan. 20–21 (including 11,794 and 2,120-share trades) at roughly $5.12–$5.05, trimming her stake. Insider CEO sales are typically viewed negatively by investors. CEO SEC Filing
• Negative Sentiment: Other senior exec selling: General Counsel John Brottem and EVP Marc Nash disclosed multi‑thousand‑share sales across Jan. 20–21 (Brottem ~10,494 shares, one filing showing ~20% reduction; Nash ~6,355 shares across filings), further increasing selling pressure from insiders. GC SEC Filing EVP SEC Filing

Analyst Upgrades and Downgrades

Several research firms have issued reports on OM. Wall Street Zen downgraded Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Royal Bank Of Canada reissued a “sector perform” rating and set a $7.00 price target on shares of Outset Medical in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. Stifel Nicolaus reduced their price objective on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 7th. Finally, BTIG Research reissued a “buy” rating and set a $17.00 price objective on shares of Outset Medical in a report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.67.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.